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PROGNOSTIC FACTORS IN INFECTIVE ENDOCARDITIS 
SARAH GRZYBINSKI 
ABSTRACT 
 
Background: Infective endocarditis (IE) is an infectious disease, most often bacterial in 
etiology, which affects the endocardial tissue layer of the heart. Despite advances in 
diagnostic technology, surgical technique, and antimicrobial therapy, IE remains a high-
mortality disease.  
Objective: This is a proposed quality improvement initiative for the Boston Medical 
Center (BMC) inpatient medicine service. The initiative aims to identify predictors of 
mortality in patients with IE, and then use the predictors to create a mortality risk-
assessment checklist. The checklist will serve as a clinical tool for medicine service 
providers to help determine if upgrade to ICU level of care is warranted. With early 
upgrade to an ICU setting, patients with a high risk of mortality will receive more 
individualized care and expedited medical intervention. The goal of this quality 
improvement initiative is to decrease mortality rate in patients with IE at BMC. 
Methods: This quality improvement initiative will implement the PDSA (plan, do, study, 
act) model for quality improvement. The checklist will be integrated into the electronic 
health record system at BMC and will be implemented over a two-year time period. Each 
PDSA cycle will last one year, and between PDSA cycles the checklist will be modified 
according to medical provider feedback. The data will be gathered through chart reviews 
to determine pre and post-checklist differences in number of transfers to the ICU and 
overall mortality rates of IE patients at BMC. 
  vi
Results: The literature review of this proposed quality improvement initiative has 
identified nine independent risk factors for mortality in patients with IE: Staphylococcus 
aureus as infective organism, New York Heart Association class IV heart failure, left 
ventricular ejection fraction < 40%, vegetation size ≥ 15 mm, age > 50 years, diabetes 
mellitus, peripheral dermatologic findings on physical examination, serum neutrophil-to-
lymphocyte ratio > 5.45, and serum D-dimer level > 4.0 mg/L. 
Conclusion: If medical providers had access to a risk assessment tool to help identify IE 
patients with a high risk of mortality, they could more accurately determine appropriate 
level of care, expedite medical intervention, and possibly reduce rates of in-hospital death 
in patients with IE.   
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 1 
INTRODUCTION 
Background 
Infective endocarditis (IE) is an infectious disease, most often bacterial in etiology, 
affecting the endocardial tissue layer of the heart. IE is characterized by vegetation 
formation – the aggregation of platelets, fibrin, and bacteria – on the cardiac valves. If 
left undetected or untreated, vegetations can result in mechanical cardiac injury, septic 
emboli, and death. IE has an average estimated annual incidence of three to nine cases 
per 100,000 persons in industrialized countries1, but recent literature suggests the 
incidence of IE in the United States is higher than the global average and may be on the 
rise. The most recent estimated incidence of IE in the United States is 15 cases per 
100,000 population.2 At Boston Medical Center (BMC), IE is particularly common given 
the high prevalence of intravenous drug use in the patient population. Despite advances in 
modern medicine, IE remains a high-mortality disease with an in-hospital mortality rate 
of 15-20% and a 1-year mortality rate approaching 40%.3 The first step to improving 
mortality rates in patients with IE is to identify factors associated with increased risk of 
mortality. If medical providers could identify patients with a high risk of mortality at the 
time of diagnosis, they could upgrade level of care to the intensive care unit (ICU), which 
may lead to improved outcomes. 
 
While there is limited objective evidence analyzing the quality of care in ICU settings 
versus general inpatient settings, the ICU, by definition, provides a higher level of care. 
The ICU has a lower nurse-to-patient ratio, allowing nurses to provide more 
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individualized care to their patients. Lower nurse-to-patient ratios result in closer 
surveillance of patients, more frequent monitoring of vital sign, and more timely 
administration of medications. Overall, ICU nurses have a higher likelihood of 
recognizing subtle changes in their patients, such as changes in skin or mental status. 
Additionally, ICU providers generally round on their patients more frequently and more 
extensively due to the critical nature of their patients’ illnesses. This allows more 
opportunities to recognize early signs of impending decompensation and intervene before 
a patient becomes unstable. Furthermore, daily patient rounds in the ICU implement a 
strong multidisciplinary team approach with physicians, nurses, social workers, and 
specialized infectious disease pharmacists to provide input on antimicrobial therapy. A 
multi-disciplinary approach has been shown to be associated with lower mortality rates 
among ICU patients.4 Finally, many providers agree that diagnostic testing and medical 
interventions occur faster in ICU settings due to a greater sense of urgency compared to 
non-ICU settings. These differences between ICU and non-ICU care are intentionally 
designed to maximize survival in complex, critically ill patients. Use of the ICU should 
generally be reserved for critically ill patients. However, certain patients with high-
mortality diseases, such as IE, may benefit from early ICU-level care.  
 
Statement of the Problem  
Despite advances in diagnostic imaging and treatment modalities, infective endocarditis 
remains a high-mortality disease. Although the reasons for continued high mortality rates 
are likely multifactorial, one of the reasons may be underestimation of disease severity at 
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the time of diagnosis. As a result, this may lead to inappropriate triaging of patients when 
admitted to the hospital, or failure to upgrade level of care after admission to a medicine 
service. At BMC and other hospitals across the United States, patients presenting to the 
emergency department (ED) with suspected IE are generally admitted to either a 
medicine floor or the ICU. However, at BMC and other high-volume emergency 
departments, thorough diagnostic workup is often limited by pressure to move patients 
through the ED quickly and admit them to an inpatient service as soon as possible. 
Consequently, patients are often not formally diagnosed with IE until after admission to 
an inpatient service. Often these patients are admitted for other problems, such as 
cellulitis or altered mental status, and are then subsequently diagnosed with IE after blood 
cultures and echocardiography are obtained.5 The decision to admit a patient to a 
medicine floor or ICU is based upon standard triage guidelines6 and clinical judgment, 
but it can be a difficult decision and may not always be clear what level of care a patient 
with IE needs. Even if a patient is correctly diagnosed with IE in the ED setting, they 
may end up inappropriately triaged to a lower level of care because they may not appear 
critically ill. Similarly, patients diagnosed with IE after admission to a general medicine 
service may appear well enough to stay in a non-ICU setting even if they have risk 
factors that substantially increase their risk of mortality. If clinicians could accurately 
identify patients at a higher risk of in-hospital death, they could intervene early by 
upgrading level of care and expediting medical therapy. 
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Hypothesis 
A risk assessment checklist that identifies mortality risk factors in patients with infective 
endocarditis is a simple and effective tool that will lead to expedited medical intervention 
and improved mortality rates. 
 
Objectives and specific aims 
This quality improvement initiative proposes to identify individual factors associated 
with increased risk of mortality in patients diagnosed with IE, and to formulate a 
mortality-risk checklist to use on patients diagnosed with IE. This mortality-risk checklist 
can then be used as a tool alongside clinical judgment to determine if upgrade in level of 
care to the ICU is warranted. The checklist will be intended for use in BMC medicine 
service patients 18 years of age and older diagnosed with IE. The checklist is not 
intended for use as a tool to downgrade level of care in patients already admitted to the 
ICU. The aims of this quality improvement initiative will be: 
1.  To identify evidence-supported factors associated with increased risk of mortality 
in patients presenting with IE 
2. To create a checklist and guidelines for BMC medicine service providers to use 
on patients diagnosed with IE as a clinical tool to help assess mortality risk and 
aide in the decision to transfer to the ICU 
3. To measure mortality rates and number of transfers to the ICU in patients at BMC 
with IE before and after checklist implementation
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REVIEW OF THE LITERATURE 
 
Pathophysiology 
Infective endocarditis is a disease of infectious etiology, most often bacterial, 
characterized by vegetation formation on the endocardium. The endocardium is the 
membranous layer of tissue lining the inside of the cardiac chambers and the surface of 
the cardiac valves. In its homeostatic form, the endocardial tissue layer is naturally 
resistant to bacterial and fungal infection, but under certain conditions can become a 
favorable environment for microorganism growth. 
 
The pathogenesis of bacterial infective endocarditis requires a specific sequence of four 
events: 1) endocardial injury, 2) platelet-fibrin complex deposition at the site of injury, 3) 
bacterial entry into the circulation as a result of an infection or a transient bacteremia 
from skin or mucosal source, and 4) bacterial adherence to the platelet-fibrin deposit and 
subsequent vegetation formation. Endocardial injury can result from a variety of insults 
to the endothelial tissue layer, but turbulent blood flow as a result of valvular disease is 
most often the causative factor in the general population. Other sources of endocardial 
injury include indwelling venous catheters, prosthetic heart valves, and presence of 
foreign material in the circulation from intravenous drug use. Once the endocardial tissue 
is injured, platelets and fibrin adhere to the exposed subendocardial tissue to form a 
platelet-fibrin complex. This platelet-fibrin complex is initially sterile but provides an 
ideal surface for bacterial adherence in the setting of bacteremia. Once bacteria have 
begun to aggregate on the platelet-fibrin complex, the complex becomes an infected 
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vegetation. The fibrin on the vegetation forms a membranous layer around the bacteria 
and protects it from host immune defenses by inhibiting chemotaxis and migration of 
phagocytes.7 
 
After a vegetation has formed on a cardiac valve, it can cause severe morbidity and 
mortality in several ways. If untreated, vegetations will ultimately cause destruction of 
the valve leaflets (Figure 1), leading to severe valvular dysfunction and subsequent heart 
failure. Vegetations can also erode into the cardiac conduction system, causing fatal 
arrhythmias. Furthermore, portions of the vegetation can embolize systemically to the 
brain, kidneys, or spleen, causing end-organ damage.7 The most common causes of death 
in patients with IE is intractable heart failure, but other common causes in these patients 
include septic shock, cerebral embolic event, and multi-organ system failure8. 
 
 
Figure 1. Gross pathology of subacute bacterial endocarditis of the mitral valve.  
The left ventricle of the heart has been opened to show mitral valve vegetations     
causing valve leaflet destruction.9 
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Although IE can affect all four cardiac valves, the most common sites of infection are the 
mitral valve (Figure 2) and aortic valve in non-intravenous drug users and the tricuspid 
valve in intravenous drug users. The mitral and aortic valves of the left side of the heart 
are classically the most common sites of infection for several reasons: 1) the relatively 
higher pressures on the left side of the heart cause more turbulent flow across the mitral 
and aortic valves, predisposing the valves to endothelial damage; 2) the relatively higher 
oxygen content on the left side of the heart is a more favorable environment for bacterial 
growth; and 3) epidemiologically, there are more acquired and congenital cardiac lesions 
on the left side of the heart. Conversely, in intravenous drug users, the right side of the 
heart is more commonly affected because the tricuspid valve is the first valve to make 
contact with blood from the venous system. Therefore, the tricuspid valve is subjected to 
repetitive micro-damage from particulate materials, such as talc, that have been injected 
into the venous system. The damaged endothelium of the tricuspid valve combined with 
bacterial translocation from the skin to the bloodstream during intravenous injection 
creates an ideal condition for vegetation formation.10 
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Figure 2. Mitral valve vegetation shown on echocardiogram.11 
RA = right atrium, RV = right ventricle, LA = left atrium, LV = left ventricle 
 
Incidence 
From 2000 to 2011, the incidence of IE in the United States steadily increased from 11 
cases per 100,000 population to 15 cases per 100,000 population, and this increase was 
consistent with Staphylococcus, Streptococcus, gram negative bacteria, and fungal IE.2 
The observed increase in IE is multifactorial, and may be in part due to longer survival of 
patients with congenital heart diseases and implanted cardiac devices. As the population 
ages, there is an increase in the incidence of degenerative valve disease in the elderly, 
placement of prosthetic valves, and exposure to nosocomial organisms. Furthermore, in 
2007, the American Heart Association (AHA) released revised guidelines for IE 
prophylaxis that restricted IE antibiotic prophylaxis to only a small group of high-risk 
patients, likely excluding other patients still at risk of developing IE.2  
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Risk Factors 
There are a number of risk factors that may predispose patients to the development of IE. 
These factors can be divided into two general categories: 1) abnormal cardiac structure or 
2) abnormal risk of bacteremia (Table 1).12 
 
Table 1. Risk factors for development of infective endocarditis 
1) Abnormal Cardiac Structure 2) Abnormal Risk of Bacteremia 
Prior endocarditis Intravenous drug use 
Rheumatic valvular disease Hemodialysis 
Aortic valve disease (including 
bicuspid aortic valve) 
Chronic indwelling venous catheter 
Prosthetic valve Poor dentition 
Unrepaired cyanotic congenital heart 
defect 
Diabetes mellitus 
 
Mitral valve prolapse 
Intracardiac devices such as pacemaker 
or implantable cardioverter defibrillator 
(ICD) 
Mitral valve regurgitation with leaflet 
thickening 
Hypertrophic cardiomyopathy 
 
Clinical Presentation and Diagnosis 
Diagnosis of IE can be difficult as it often presents with a wide range of vague 
symptoms. Patients with IE may present acutely, but more often present subacutely. 
Patients presenting with subacute IE may have nonspecific symptoms of fevers, chills, 
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night sweats, anorexia, weight loss, and fatigue. Patients presenting with advanced IE 
may present with congestive heart failure, cardiac arrhythmias, systemic emboli 
manifesting as stroke, pulmonary embolism (in right-sided IE), and myocardial 
infarction.  
 
Physical examination in patients with IE classically reveals peripheral septic emboli and 
immune complex deposition. Septic emboli may manifest in two ways: 1) splinter 
hemorrhages on the nail beds, or 2) Janeway lesions, which are non-tender hemorrhagic 
macules on the palms, soles, or distal digits (Figure 3). Immune complexes manifest as 
Osler’s nodes, tender nodules on the pads of the digits. Other peripheral stigmata include 
proximal nail bed splinter hemorrhages and petechiae of the extremities. These peripheral 
changes, however, are only present in approximately 3-5% of patients presenting with IE 
and therefore are rarely useful in the diagnosis of IE.3 
 
 
Figure 3. Peripheral dermatologic stigmata of infective endocarditis. A) Janeway lesions on distal 
digits; B) Splinter hemorrhages on nail beds.13 
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Unlike the peripheral dermatologic exam, the cardiovascular physical exam is 
tremendously valuable in the diagnosis of IE. The presence of a new murmur is reported 
in 48% of IE cases and the worsening of a known murmur is reported in 20% of IE 
cases.1 Other less common physical exam findings in patients with IE may include tender 
splenomegaly, arthritis, and changes in mental status.  
 
Two of the most important studies for the diagnosis of IE are peripheral blood cultures 
and echocardiography. At least three sets of peripheral blood cultures should be obtained 
before initiation of antibiotic therapy. A transthoracic echocardiogram (TTE) can be 
performed as a screening test if a transesophageal echocardiogram (TEE) is not 
immediately available, but a TEE has a higher specificity and sensitivity and is therefore 
the preferred diagnostic test. Transesophageal echocardiography is, however, a more 
invasive procedure and is associated with higher risk of complications, such as 
esophageal perforation. Therefore, it should only be used when there is moderate to high 
clinical suspicion of IE.14 
 
The most widely accepted guidelines for the diagnosis of IE are the Duke Criteria. 
Originally proposed by Durack et al.15 and the Duke Endocarditis Service in 1994, this 
set of criteria aimed to assist in the diagnosis of IE. The Duke Criteria for diagnosis of IE 
is still used today in a modified form (Table 2). According to the Modified Duke Criteria, 
the diagnosis of IE is definitively made if any of the following criteria are met: two 
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major; or one major and any three minor; or five minor; or histologic findings consistent 
with IE; or positive gram stain or culture of specimen obtained from surgery or autopsy. 
 
Table 2. Modified Duke Criteria for the diagnosis of infective endocarditis16 
Major Criteria Minor Criteria 
I. Positive blood culture defined as either 
A, B, or C: 
A. Typical microorganism for IE from 
two separate blood cultures: 
1. Streptococci viridans, S. bovis, 
HACEK group; or 
2. Staphylococcus aureus or 
enterococci in absence of primary 
focus 
B. Persistently positive blood cultures 
defined as microorganism consistent 
with IE from: 
1. Blood cultures drawn >12 hours 
apart; or 
2. All of three or majority of 4 or 
more separate blood cultures 
drawn at least 1 hour apart 
C. Single positive blood culture for 
Coxiella burnetii or antiphase I IgG 
antibody titer >1:800 
II. Endocardial involvement defined as 
either A or B: 
A. Positive echocardiogram for IE 
defined as one of the following: 
1. Oscillating intracardiac mass, or 
2. Myocardial abscess, or 
3. New partial detachment of 
prosthetic valve 
B. New valvular regurgitation 
I. Predisposing heart condition or 
intravenous drug use 
II. Fever (38°C or 100.4°F) 
III. Vascular phenomena defined as: 
A. Major arterial emboli 
B. Septic pulmonary infarcts 
C. Mycotic aneurysm 
D. Intracranial hemorrhage 
E. Conjunctival hemorrhage 
F. Janeway lesions 
IV. Immunologic phenomena defined as: 
A. Glomerulonephritis 
B. Osler’s nodes 
C. Roth spots 
D. Rheumatoid factor 
V. Positive blood culture not meeting 
major criteria OR serologic evidence of 
active infection with organism consistent 
with IE 
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Treatment 
Treatment of IE can vary between institutions and depends on patient population, 
common infective organisms in those populations, and population-specific antibiotic 
resistance. However, general treatment principles remain the same across most 
institutions. There are two general treatment interventions for IE: medical therapy and 
surgical therapy. Medical treatment consists of antimicrobial therapy targeted to the 
specific microorganism. It may take several days to obtain results from blood cultures, so 
it is important to select early appropriate empiric therapy based on suspected pathogen. 
Empiric antibiotic therapy should cover staphylococci (both susceptible and resistant), 
streptococci, and enterococci, as these are the most common infective organisms in IE. 
Once the pathogen is identified, the optimal treatment involves an antibiotic that is 
bactericidal, administered through a parenteral route, and given for a prolonged course of 
therapy.14 
 
Some patients diagnosed with IE are considered surgical candidates depending upon a 
variety of factors including infective organism, vegetation size, and presence of 
perivalvular infection, emboli, or heart failure. The strongest indications for surgical 
intervention in patients presenting with IE is in patients with fungal-induced IE, patients 
with valve dysfunction resulting in signs and symptoms of heart failure, and IE 
complicated by heart block, annular or aortic abscess, or destructive penetrating lesions. 
The full medical and surgical treatment guidelines are beyond the scope of this literature 
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review, but the AHA has released the full 2015 guidelines for antimicrobial therapy and 
surgical indications for IE.14 
 
Prevention 
Antibiotic prophylaxis of IE is recommended for certain patients with cardiac conditions 
that put them at increased risk of developing IE. The newest IE prophylaxis guidelines 
were released by the AHA in 2007. These include four cardiac conditions for which 
antibiotic prophylaxis is reasonable, and four procedures that warrant prophylaxis in 
these patients. According to the AHA guidelines, patients considered candidates for 
prophylaxis are those with one or more prosthetic heart valve, prior history of 
endocarditis, congenital heart disease, and cardiac transplant recipients who develop 
cardiac valve abnormalities. Patients who fit into any of these four categories of cardiac 
conditions are advised to use prophylactic antibiotic therapy when undergoing dental 
procedures, upper respiratory tract procedures, genitourinary or gastrointestinal 
procedures (only if those systems are actively infected), and procedures on infected skin 
or infected musculoskeletal tissue.17 
 
Existing research 
Staphylococcus aureus 
Numerous studies have investigated infectious pathogen as a predictor of mortality in 
patients with IE. While staphylococci and streptococci are the two most common 
pathogens identified as the cause of IE, infection with Staphylococcus aureus (S. aureus) 
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has been identified across multiple studies as one of the strongest independent predictors 
of mortality in patients with IE. Chu et al. conducted a study of 267 patients with IE and 
found that patients with S. aureus as the causative organism were more than twice as 
likely to die during their hospital admission compared to patients with other causative 
pathogens (OR 2.06; 95% CI, 1.01 to 4.20).18 A smaller study by Gotsman et al.19 
compared clinical features from a group of 100 patients with IE and analyzed the 
differences between the patients who died and the patients who survived. The study 
found that 25% of patients who died from IE had S. aureus as the causative organism, 
while only 5% of patients who survived had S. aureus infection (P<0.005), concluding 
that S. aureus is a significant predictor of mortality. 
 
In the era of increased healthcare exposure and antibiotic resistance, methicillin-resistant 
S. aureus (MRSA) infection is becoming a more common causative pathogen of IE, and 
is associated with exceptionally high mortality rates. A large retrospective study recently 
published in December 2015 analyzed data of 248 ICU patients with IE and found that 
patients with IE due to MRSA had a nearly five-fold increased risk of mortality (OR 
4.981, 95% CI: 1.433-17.306; P=0.0115).20 A study from 2015 by Hase et al. analyzed 
mortality in IE patients over a 14-year period at a hospital in Japan. The study found that 
patients with methicillin-sensitive S. aureus (MSSA) infection had only a slightly higher 
increased risk of mortality, but patients with MRSA had a thirteen-fold greater risk of in-
hospital mortality (OR 13.00, 95% CI, 3.21-76.4, P<0.001). In 2012, Leitman et al.21 
investigated factors associated with mortality and found through multivariate analysis 
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that both MRSA and MSSA infection were predictors of mortality, but MRSA infection 
was found to be the strongest predictor of mortality. In this study, patients with MRSA 
infection had a mortality rate of 45%, and mortality rate increased to 50% in patients who 
had both MRSA infection and age greater than 60 years. 
 
Heart Failure 
One of the most widely recognized factors associated with a high risk of mortality is 
presence of heart failure. Studies have examined both functional class of heart failure and 
left ventricular ejection fraction (LVEF) as independent predictors of mortality in patients 
with IE. Functional class of heart failure is most often recognized as the New York Heart 
Association (NYHA) classification system for heart failure. The NYHA heart failure 
scale classifies patients based on symptoms such as dyspnea and fatigue, and how much 
these symptoms limit daily physical activity. NYHA classes of heart failure range from 
class I (least severe) to class IV (most severe). NYHA Class IV heart failure is defined as 
dyspnea and fatigue that severely limits activity and is present even at rest.7 
 
De Feo et al.22 recognized a need for a specific risk prediction system in IE and analyzed 
predictors of post-operative mortality in 440 native valve IE patients. Through logistic 
regression analysis, the study concluded that patients with NYHA Class IV heart failure 
at the time of IE diagnosis were more than five times more likely to die than patients 
without heart failure or with less severe heart failure (OR 5.913; 95% CI, 2.569-13.612, 
P<0.001). A similar study, conducted by Costa et al., investigated 186 patients with IE. 
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This study also showed a significant increased risk of mortality in patients with NYHA 
Class IV heart failure compared to patients with less severe heart failure (OR=5.16, 
P<0.0001).23 
 
A retrospective observational cohort study in 2003 aimed to develop a prognostic 
classification system for adults with left-sided endocarditis.24 This study analyzed factors 
associated with mortality at six months after diagnosis of IE, and concluded that 
moderate to severe congestive heart failure is independently associated with higher 
mortality rates. The drawback of this particular study is that they did not use NYHA 
classifications of heart failure, but rather classifications of mild, moderate, or severe heart 
failure. They defined moderate to severe heart failure as having at least one of the 
following: shortness of breath at rest, rales on physical exam, or evidence of pulmonary 
edema on chest radiograph. This definition of heart failure can be translated into the 
NHYA classification system because patients with NYHA Class IV heart failure meet the 
study’s criteria for moderate to severe heart failure.  
 
Left Ventricular Ejection Fraction 
Several studies have investigated left ventricular ejection fraction (LVEF) as a predictor 
of outcome in patients with IE. LVEF is defined as the fraction of end-diastolic blood 
volume ejected from the left ventricle during each contraction of the heart. Normal LVEF 
ranges from 55% to 75%.7 LVEF is an objective measurement of heart muscle function 
obtained from echocardiography. Echocardiography is an ideal screening tool because it 
 18 
is low-cost, easy to use, and has a low risk of complications. Lauridsen et al. investigated 
LVEF as a predictor of mortality in patients with S. aureus left native valve IE. The 
retrospective study included a large cohort of 1379 patients and analyzed data from both 
transthoracic and transesophageal echocardiograms. The study concluded that patients 
with an LVEF <40% in the setting of S. aureus IE had a three-fold increase in mortality 
at one year compared to patients with an LVEF >40% (OR, 3.01; 95% CI, 1.35-6.04; 
P=0.004).25  
 
Two additional smaller studies have analyzed LVEF as a predictor of outcome in patients 
with IE, but used higher LVEF cutoff values. Turek et al.26 and Tok et al.27 analyzed 
multiple variables as independent risk factors for IE, including LVEF <50%. Both studies 
found a significant increase in in-hospital mortality in patients with an LVEF<50%. 
 
Vegetation Size 
The size of vegetation, as measured on echocardiography, has been shown across 
multiple studies to significantly increase risk of mortality. Thuny et al.28 performed a 
prospective, multicenter analysis of 384 patients and used a vegetation size of 15 mm to 
predict risk of mortality. The study concluded that patients with a vegetation size of 
greater than 15 mm were at a significantly higher risk of death at one year than patients 
with a vegetation size of 15 mm or less (RR 1.8; 95% CI 1.10 to 2.82; p=0.02). A smaller 
study from Gotsman et al.19 investigated 100 cases of IE and found vegetation size to be 
an independent risk of mortality. This study found the risk of mortality to be 5.3%, 10%, 
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and 27% in patients with a vegetation size of <10 mm, 10-15 mm, and >15 mm, 
respectively. An additional study of 146 patients found that vegetation size ≥ 10 mm was 
associated with higher rates of mortality, especially in patients with older age and MRSA 
infection.21 Vegetation size is a measurement that can easily be obtained at the bedside 
with echocardiography and can greatly impact chance of survival, making it a useful tool 
for the proposed mortality risk checklist. 
 
Age 
Although endocarditis affects patients from a wide range of ages, several studies have 
investigated the association between age and mortality. In one of the largest IE 
population-based studies to date, Muñoz et al.29 studied 1804 patients with IE from 1960 
to 2008 and determined that older age is an independent risk factor for in-hospital 
mortality. This study compared the difference in age between patients in the survival 
group and patients in the mortality group and found the median age in the survival group 
was 67.6 years while the median age in the mortality group was 73 years, They 
concluded that age above 67 adds a 2% risk of mortality (OR 1.02; 95% CI 1.01 to 1.03; 
p<0.01). An additional study of 186 patients aimed to develop a risk index for in-hospital 
death in patients with IE and used age ≥ 40 as one of the factors. The study found a four-
fold increased risk of mortality in patients 40 years of age and older compared to the 
group younger than 40 years of age (OR 4.16; 95% CI 1.63-10.80; p<0.0001)23. Three 
additional studies also found increasing age to be a significant predictor of mortality in 
IE. 30,22,31 Although none of these studies defined an exact cutoff age at which mortality 
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increases, they all concluded there is a significantly increased risk of mortality as age 
increases in patients with IE.  
 
Diabetes Mellitus 
Patients with diabetes mellitus tend to have higher rates of infections and more 
complicated courses associated with infection compared to patients without diabetes. 
This phenomenon is likely related to the adverse effects of hyperglycemia on immune 
function.32 From 1996 to 2001, Chu et al.18 collected data from 267 patients with IE, and 
found through logistic regression modeling that the presence of diabetes mellitus was 
associated with a two-fold greater likelihood of in-hospital death in patients with IE (OR 
2.48; 95% CI, 1.24 to 4.96). In a second study, Kourany et al.33 studied 1055 patients 
from the International Collaboration on Endocarditis Merged Database (ICE-MD) and 
found that diabetes mellitus is an independent predictor of in-hospital mortality in 
patients with IE (OR 1.71; 95% CI, 1.08 to 2.7). The ICE-MD study is unique in that it is 
one of the largest IE studies, and the only multinational study that has analyzed mortality 
in patients with IE from four European countries and the United States. Medical 
providers should always consider patients with diabetes mellitus, type I or type II, to be at 
higher risk for complications and mortality across all disease states, but especially in IE. 
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Peripheral Dermatologic Findings 
Although peripheral dermatologic changes on physical examination are rare in patients 
with IE3, the presence of these skin changes indicates a poor prognosis. An observational, 
prospective study by Servy et al.34 in 2014 collected data from 487 patients with IE. Of 
the 487 patients, 11.9% had some form of dermatologic manifestation including purpura, 
Osler nodes, Janeway lesions, or conjunctival hemorrhages. Although this study did not 
find a direct association between dermatologic lesions and mortality, it did conclude that 
peripheral dermatologic changes in patients with IE is associated with greater risk of 
embolic events, particularly cerebral emboli. In this study, 32.8% of the patients with 
dermatologic manifestations suffered a cerebral embolic event, compared to 18.4% in the 
group of patients without dermatologic findings.  
 
A study by Lee et al. investigated embolic events as predictors of mortality and found 
that embolic events, both extra-cerebral and cerebral, significantly increase risk of in-
hospital mortality in patients with IE (RR 3.510; 95% CI, 1.271 to 9.69).35 Therefore, 
since peripheral dermatologic changes increase risk of embolic events, and embolic 
events increase risk of mortality, it is accurate to conclude that peripheral dermatologic 
changes such as purpura, Osler nodes, Janeway lesions, and conjunctival hemorrhages are 
associated with increased risk of mortality. There is a lack of literature that directly links 
the association between dermatologic findings and mortality, but this is likely because 
dermatologic manifestations of IE are exceedingly rare. However, the presence of these 
dermatologic findings makes an ideal component for the risk-assessment checklist 
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because, unlike laboratory tests and imaging, physical examination is a quick, non-
invasive screening tool.  
 
Serum Neutrophil-to-Lymphocyte Ratio 
Elevated serum neutrophil-to-lymphocyte ratio is a marker of inflammation that is known 
to be associated with higher rates of mortality in patients across multiple disease 
spectrums, including sepsis, cancer, and trauma.36 However, there are very few studies 
specifically analyzing neutrophil-to-lymphocyte ratio as a predictor of outcome in 
patients with IE. In 2014, Bozbay et al.37 released a study that retrospectively analyzed 
mortality in 171 patients with IE. Patients defined as having a high neutrophil-to-
lymphocyte ratio (>5.46) were found to have a significantly higher in-hospital mortality 
rate of 39.5% compared to patients with a neutrophil-to-lymphocyte ratio <5.46, who had 
an in-hospital mortality rate of 18.9%. An additional retrospective study from Turak et 
al.38 also found a significant association between elevated neutrophil-to-lymphocyte ratio 
and mortality, but this study used a cutoff neutrophil-to-lymphocyte ratio of 7.1. The 
association between neutrophil-to-lymphocyte ratio and mortality in IE needs further 
investigation, but considering these recent findings in the literature and the overall 
association between elevated ratio and mortality in patients with other critical illnesses, it 
will be a useful biochemical value to include on the IE mortality-risk checklist. 
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Serum D-Dimer Level 
D-dimer is a fibrin degradation product deposited in the blood after fibrin cross-links are 
degraded by fibrinolyis. Serum D-dimer level is a specific measurement of fibrin 
turnover and is often used to predict thrombotic and hemorrhagic adverse events.39 While 
serum D-dimer level is most often utilized as a diagnostic tool in thromboembolic events 
such as deep vein thrombosis and pulmonary embolism, there is literature suggesting it 
can be used to predict outcome in patients with IE. A prospective, observational study of 
157 patients with IE found that elevated serum D-dimer levels were significantly 
associated with in-hospital mortality (HR 1.32; 95% CI, 1.24 to 1.40; p<0.001). 
Furthermore, this study found that a serum D-dimer level ≥4.2 mg/L has a sensitivity of 
86% and specificity of 85% in predicting in-hospital death in patients with IE.26 It is 
important to note that for the purpose of the mortality risk-assessment checklist proposed 
in this study, serum D-dimer level would not be a diagnostic test for presence of 
thromboembolism, but rather a component to assess overall risk of mortality. 
 
Other factors 
Other mortality risk factors that have been reported in single studies but have limited 
additional data include: elevated serum beta-natriuretic peptide level,40 female gender,30 
elevated C-reactive protein level,41 and elevated white blood cell count.41 These factors 
need further investigation regarding their contribution to mortality in IE, and therefore 
will not be included in the proposed mortality risk checklist. 
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Numerous studies have investigated factors contributing to mortality in patients with IE, 
but few studies have attempted to create a prognostic classifications system in IE. 
Although not all studies agree on the same predictors of mortality, the aforementioned 
risk factors in this literature review have been agreed upon by multiple reliable studies as 
independent predictors of mortality. Furthermore, these factors are easy to identify 
through laboratory testing, diagnostic imaging, and physical examination. 
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METHODS 
Study design 
This is a quality improvement initiative for the Boston Medical Center inpatient medicine 
service with deployment of an infective endocarditis mortality risk factor screening tool 
that prospectively measures upgrade in level-of-care rates and overall mortality. 
 
Study population and sampling 
The study population for this quality improvement initiative will be BMC medicine 
service patients age 18 years or older with IE, as defined by the Modified Duke Criteria. 
Each year, approximately 20% of the 130,000 emergency department visits at BMC 
result in an admission, for a total of 26,000 admissions with varying diseases.42 IE is not 
a reportable disease to the Centers for Disease Control and Prevention (CDC) and rates of 
IE are not recorded at BMC. However, given the urban setting of BMC and the high 
prevalence of intravenous drug use in the patient population, the rate of IE at BMC is 
likely higher than the national average. An accurate sample size for this study cannot be 
calculated until patient medical records have been reviewed retrospectively and the exact 
annual incidence of IE at BMC is calculated. The patient inclusion and exclusion criteria 
for this quality improvement initiative can be found in Table 3. 
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Table 3. Patient inclusion and exclusion criteria 
 
Inclusion Criteria Exclusion Criteria 
1. Patients 18 years of age or older 1. Patients less than 18 year of age 
2. Diagnosis of IE during current 
admission as defined by the modified 
Duke criteria 
 
2. Admitted to the ICU or ICU step-down 
service at time of diagnosis of IE 
3. Admitted to a non-ICU medicine 
service at time of diagnosis of IE 
 
 
Intervention 
This study will follow the PDSA model for quality improvement initiatives. The PDSA 
cycle is a four-stage, quality improvement model used for implementing change. The four 
stages of the PDSA cycle are 1) Plan, 2) Do, 3) Study, and 4) Act.43  
 
Plan 
This study will recruit a multidisciplinary team of BMC department of medicine 
personnel, including the Chief of Medicine, the Office of Quality Improvement and 
Patient Safety, attending physicians, physician assistants, nurse practitioners, medical 
residents, and nurse managers. Key opinion leaders will be invited to partake in a 
discussion and provide their input on the current management of patients with IE at 
BMC. They will also provide input on optimal strategies for implementation of the 
project. Their buy-in will provide useful top-down management leadership. 
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The nine mortality risk factors identified in the literature review will be implemented into 
a checklist. The checklist will be integrated into the EpicCare Inpatient Certified 
Electronic Health Record software [2014 Verona, WI] at BMC. The checklist will be a 
prompt that automatically appears on the medical record interface when the diagnosis of 
IE is entered into a patient’s record. Providers must complete the checklist by clicking 
items that apply to the patient. Providers will be strongly encouraged to use the checklist 
as a tool to assist in their clinical decision-making but they will not be required to follow 
the guidelines regarding upgrading level of care. The checklist should be viewed as 
additional data to use in the context of appropriate clinical judgment when deciding plan 
of care for patients with IE. 
 
Providers will decide if upgrading level of care to the ICU setting is appropriate based on 
a two-tiered classification system. Items on the checklist with a risk classification of 
“high” are items that have evidence to support them as strong independent predictors of 
mortality. A single high-risk item may increase a patient’s risk of mortality enough to 
warrant ICU admission. Items with a risk classification of “moderate” are also 
independent predictors of mortality, but have not been shown to increase risk of mortality 
as much as high-risk items. The proposed mortality risk-assessment checklist, along with 
the guidelines for interpreting the results of the checklist, is shown in Table 4. 
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Table 4. Mortality risk-assessment checklist and guidelines for upgrading level of 
care in patients with IE 
Risk Factor Risk Classification 
Staphylococcus aureus infection HIGH 
NYHA Class IV heart failure 
 
HIGH 
Left ventricular ejection fraction <40% 
 
HIGH 
Vegetation size ≥ 15 mm 
 
HIGH 
Age > 50 years MODERATE 
Diabetes mellitus MODERATE 
Peripheral dermatologic findings on physical 
examination 
 
MODERATE 
Serum neutrophil to lymphocyte ratio > 5.46 
 
MODERATE 
Serum D-dimer > 4.0 mg/L MODERATE 
 
Guidelines: 
• 1 or more HIGH items: potentially high risk; recommend transfer to ICU 
• 2-4 MODERATE items: consider transfer to ICU based on patient stability 
• 0-1 MODERATE items: low risk profile but consider transfer to ICU based on patient 
stability 
 
Do 
The first intervention period will begin after the planning phase. The risk-assessment 
checklist will be e-mailed from the Chair of Medicine to all medicine service and ICU 
attending physicians, resident physicians, physician assistants, and nurse practitioners. 
Although ICU providers will not be using the checklist to determine course of care in 
their patients, it is important for these providers to be familiar with the checklist so they 
can have an understanding of predicted mortality in IE patients transferred to the ICU. In 
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addition to integrating the checklist into the electronic medical record system, the 
checklist will also be distributed in paper form to display at workstations as a reference. 
A presentation will be given before the first intervention period at the Department of 
Medicine Grand Rounds to inform providers about this new tool and initiative.  
 
Study  
This quality improvement project will measure two outcomes before and after 
implementation of the checklist:  
1) Mortality rate in patients diagnosed with IE at BMC 
2) Number of patients transferred to the ICU after diagnosis of IE 
 
Data will be collected retrospectively through two separate chart reviews. The first chart 
review will be completed before the checklist intervention and will include a review of 
medical records of all patients diagnosed with IE at BMC during the two years prior to 
this quality improvement initiative. This first chart review will determine the number of 
IE cases at BMC, mortality rate of IE at BMC, and rate of transfer to the ICU in patients 
with IE. The data collected during this first chart review will be pre-intervention data. 
 
The second chart review will be a post-intervention review and will take place after the 
24-month intervention period. This review will determine incidence of IE at BMC during 
the intervention period, mortality rate in patients with IE at BMC during the intervention 
period, and rate of transfer to the ICU in patients with IE during the intervention period. 
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After the data is collected from the second chart review, the pre-intervention and post-
intervention data will be compared. A paired t-test will be used to analyze the difference 
between pre-intervention and post-intervention rates of transfer to the ICU in IE patients 
and overall mortality rate in IE patients at BMC. 
 
Act 
After the first 12-month intervention period, feedback will be obtained from providers 
about what is working well with the checklist and how it could be improved. The 
checklist will be edited according to the feedback, and re-implemented for an additional 
12-month intervention period. The final data collection will take place after the second 
intervention period. After finalizing the results of the mortality-risk assessment checklist, 
a discussion will be held with the BMC medicine service leadership personnel to 
determine if the checklist should be permanently integrated into the medical record 
software at BMC. If the results show a significant decrease in mortality rate, it may be 
reasonable to make the checklist a strict BMC guideline for upgrading level of care. If 
there is no significant decrease in mortality after implementation of the checklist, 
providers may feel that it is still a useful educational tool and reference when determining 
plan of care for patients with IE. 
 
Timeline and resources 
The entire quality improvement initiative will take place over a 3-year time span with two 
PDSA cycles (Table 5). Months 1-19 will comprise the first PDSA cycle, while months 
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20-36 will comprise the second PDSA cycle. The mortality risk-assessment checklist will 
be used for a total of 24 months to maximize sample size. 
 
Table 5. Timeline for IE mortality risk-assessment quality improvement initiative 
Month Plan 
 
1 
Meet with medicine service personnel to gather input on current IE management 
and introduce the proposed quality improvement initiative. 
 
1-4 
Perform a retrospective chart review of patient medical records from the past 2 
years at BMC to determine annual incidence, mortality rate, and ICU transfer rate 
of IE patients at BMC. 
 
 
 
 
5 
Introduce the finalized checklist to medicine service personnel and gather their 
feedback on the checklist. Make changes to the checklist and implementation plan 
based on feedback. 
 
With the help of Epic software technicians, incorporate the checklist into the Epic 
system as an automated pop-up prompt that will appear on the computer screen 
when the diagnosis of IE is entered into a patient’s record. 
 
 
6-17 
Implement the proposed mortality risk-assessment checklist on inpatient medicine 
floors at BMC. 
 
 
18-19 
Gather feedback from medicine service providers about problems they have 
encountered while using the checklist and ideas for improving the checklist. 
 
Use provider feedback to make appropriate changes to the checklist. 
 
 
20-31 
Re-implement the improved risk-assessment checklist for a second 12-month 
period.  
 
 
 
32-35 
Review the medical records of all patients diagnosed with IE during the 24-month 
intervention period. Use statistical analysis software to analyze pre-intervention and 
post-intervention mortality rate and number of transfers to the ICU. 
 
 
36 
Meet with medicine service personnel to present the results of the study and discuss 
options for further implementation of the checklist at BMC. 
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Institutional Review Board 
This study will be submitted to the Boston University Institutional Review Board (IRB) 
for expedited review. Although quality improvement initiatives are generally exempt 
from IRB approval, this study involves a chart review with patient identifiers, qualifying 
it as a study with human subjects.44 Therefore, this study does not meet exemption 
criteria.  
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CONCLUSION 
Discussion 
This proposed QI initiative has the potential to be an effective tool in the management of 
IE. However, it has several limitations. This study only analyzes in-hospital mortality rate 
and therefore may underestimate overall mortality rate. Some patients that suffer life-
altering complications of IE during their hospital course, such as stroke, may end up 
being transferred to nursing facilities and ultimately expire at the facility due to the long-
term sequela of IE.  
 
Additionally, it is possible that this QI initiative will not decrease mortality rates as 
intended. Patients who have more mortality risk factors will, by definition, have a higher 
risk of mortality. Although this study’s rationale is based on the theory that ICU level of 
care will improve outcome in patients, ICU level of care may not be enough to prevent 
death in patients who already have an extremely high risk of mortality. 
 
It is important to note that this initiative is not intended to quantify the attributable risk 
reduction in mortality, but rather to achieve expedited care and overall mortality 
reduction based on a system change. Every individual item on the mortality risk-
assessment checklist contributes to increased risk of mortality, but the risk reduction from 
implementing this checklist and upgrading level of care cannot be quantified with the 
proposed methodology. 
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An anticipated obstacle of this initiative is gaining the cooperation of all medicine service 
providers and ICU providers. Some of the patients who may be classified as high-risk for 
mortality according to the checklist may not appear critically ill. For example, a patient 
may have a 15mm vegetation and S. aureus infection but may be hemodynamically 
stable. Medicine service providers may be hesitant to use the proposed guidelines to 
upgrade level of care. Critical care providers may also be hesitant to accept patients as a 
transfer to the ICU if they do not have a true medical requirement for being in the ICU, 
such as mechanical ventilation, blood pressure support, or insulin infusion.  
 
Furthermore, this is not a low-cost initiative. While the cost of implementing the 
checklist itself is inexpensive, the cost of an ICU admission is substantially higher than 
the cost of a general inpatient admission. A more extensive cost-benefit analysis may be 
required. 
 
There is still a considerable amount of research needed regarding the prevention and 
management of IE. If the United States continues to experience increasing rates of IE, the 
focus of research may need to be shifted towards more effective prevention strategies. 
Although this is a single-center QI initiative at BMC, it is potentially generalizable to 
other large, urban-setting medical centers that experience high rates of IE. 
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Summary and Clinical Significance  
IE is a high-mortality disease with a rising incidence in the United States. Despite 
innovations in medical therapy, many patients with IE suffer life-altering complications 
and death. This QI initiative proposal investigated factors associated with mortality, and 
used these factors to formulate a mortality risk assessment checklist for the BMC 
inpatient medicine department. An extensive literature review was conducted and 
revealed nine independent predictors of mortality in patients with IE: Staphylococcus 
aureus as infective organism, NHYA class IV heart failure, LVEF < 40%, vegetation size 
≥ 15 mm, age > 50 years, diabetes mellitus, peripheral dermatologic findings on physical 
examination, serum neutrophil-to-lymphocyte ratio > 5.45, and serum D-dimer level > 
4.0 mg/L. These risk factors were incorporated into a two-tiered checklist with guidelines 
for using the checklist as a clinical tool to determine if transfer to the ICU is warranted. 
In theory, patients with a high risk of mortality may have a better chance of survival if 
they receive early, individualized, expedited care in an ICU setting. 
 
Very few studies have recognized the need for an IE prognostic classification system. 
While many studies have identified risk factors for mortality in IE, most of these studies 
fail to propose an intervention for patients with a high risk of mortality. This QI initiative 
proposal fills some of the existing gaps in the literature by synthesizing data from 
numerous studies and using the data to propose a specific intervention. This is a novel 
mortality-risk assessment tool that could potentially lower mortality rates in patients with 
IE at BMC and other medical institutions across the United States. 
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LIST OF JOURNAL ABBREVIATIONS 
 
Am J Med The American Journal of Medicine 
Ann Intensive Care Annals of Intensive Care 
Arch Intern Med Archives of Internal Medicine 
Can J Cardiol The Canadian Journal of Cardiology 
Cent Eur J Med The Central European Journal of Medicine 
Circ Cardiovasc Imaging Circulation: Cardiovascular Imaging 
Clin Chem Clinical Chemistry 
Clin Infect Dis Clinical Infectious Disease 
Crit Care Med Critical Care Mdicine 
Eur Heart J Cardiovasc Imaging European Heart Journal: Cardiovascular Imaging 
IMAJ The Israel Medical Association Journal 
Immunol Med Microbiol Immunology and Medical Microbiology 
Int J Cardiol The International Journal of Cardiology 
Int J Infect Dis The International Journal of Infectious Diseases 
J Am Coll Cardiol The Journal of the American College of Cardiology 
JAMA The Journal of the American Medical Association 
J Heart Valve Dis The Journal of Heart Valve Disease 
J Korean Med Sci The Journal of Korean Medical Science 
J Trauma Acute Care Surg The Journal of Trauma and Acute Care Surgery 
NEJM The New England Journal of Medicine 
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Rev Bras Circ Cardiovasc The Revista Brasileira de Cirurgia Cardiovascular 
Scand J Infect Dis The Scandinavian Journal of Infectious Diseases 
Sci World J The Scientific World Journal 
Thromb Res Thrombosis Research 
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